Clinical trials: Cancer Patient
Breast Cancer
HER2-positive Breast Cancer Project Initiated by Investigators
This study will assess the objective response rate (ORR), safety, progression-free survival (PFS) , overall survival (OS), 6-month survival rate, 12-month survival rate, 18-month survival rate, 24-month survival rate, disease…
- Trial name
- NCT05346328
- Testing
- Injection of A166
- Volunteers
- 48 people
- Sponsor
- Fudan University
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
This phase II MATCH treatment trial tests how well MLN0128 (TAK-228) works in treating patients with cancer that has certain genetic changes called TSC1 or TSC2 mutations.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390865
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
This phase II trial studies the side effects and how well clofarabine works when given together with low-dose total-body irradiation (TBI) in treating patients with acute myeloid leukemia (AML) undergoing donor peripheral blood…
- Trial name
- NCT01252667
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Clofarabine, Cyclosporine
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Fred Hutchinson Cancer Center
Basal Cell Carcinoma
A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)
This prospective, observational, cohort study is designed to assess the effectiveness and safety outcomes of vismodegib and to assess actual day-to-day disease and participant management by the physician.
- Trial name
- ROSETT (NCT02371967)
- Testing
- Vismodegib
- Where
- 4 sites in Sweden
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia
Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients
The purpose of the study is to determine whether it is possible to improve the immune response rate to 'flu vaccination in patients with chronic lymphocytic leukaemia (CLL).
- Trial name
- CLLIFVAC (NCT00596336)
- Testing
- Imiquimod cream, influenza vaccine
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- The Royal Bournemouth Hospital
Pulmonary Embolism, Deep Vein Thrombosis
Multi-Center Human Alert Trial to Prevent DVT and PE
To evaluate physician response to human alerts that inform the clinician that his/her patient may be eligible for thromboprophylaxis.
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
- Trial name
- NCT00409136
- Testing
- Human Alert
- Where
- 26 sites in United States
- Volunteers
- 2,496 people
- Sponsor
- Brigham and Women's Hospital
Colorectal Cancer
The Investigation of the EtCO₂- PaCO₂ Relation During Laparoscopic Colon Surgery
Et-C02 is used to predict PaCO2 during surgery. There are controversies regarding the value of ETCO2 to predict PaCO2. The aim of this study was to investigate the relation between Et-CO₂ and PaCO₂ measurements in patients…
- Trial name
- NCT01707511
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Diskapi Teaching and Research Hospital
Fuchs Endothelial Corneal Dystrophy
Prevalence of Fuchs Endothelial Corneal Dystrophy in a Population of Dermatology Patients.
The prevalence of Fuchs Endothelial Corneal Dystrophy (FECD) varies from 3.7 to 21.6% of adults depending on the population studied (country and age class), the method of diagnosis and the definition adopted.
- Trial name
- NCT07117071
- Testing
- collection of medical data
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
PHENYTOIN/SORAFENIB [VA Drug Interaction], Carcinoma, Hepatocellular
TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma
TACE is widely used in patients with unresectable HCC. However, it is a non-curative approach; thus ,strategies to further improve the survival of these patients are needed.
- Trial name
- NCT01605734
- Testing
- TACE, sorafenib combined with TACE
- Where
- 5 sites in China
- Volunteers
- 120 people
- Sponsor
- Shandong Cancer Hospital and Institute
Thyroid Neoplasms, Hypothyroidism
Individual Dosing of Levothyroxine After Thyroidectomy
Recently, Zaborek et al. raised a Poisson regression model for levothyroxine(LT4) dosing scheme to predict individual dose of LT4 after thyroidectomy: daily LT4 dose=e[2.02+0.01(W)-0.0037(A…
- Conditions
- Thyroid Neoplasms, Hypothyroidism, Surgery
- Trial name
- NCT05240911
- Testing
- Levothyroxine Sodium Tablets
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Head and Neck Neoplasms, Recurrent Disease
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
This trial is a multicenter, prospective, single-arm exploratory clinical study to evaluate the efficacy and safety of Penpulimab injection combined with cetuximab in the first-line treatment of recurrent/metastatic squamous cell…
- Conditions
- Head and Neck Neoplasms, Recurrent Disease, Metastatic Cancer
- Trial name
- NCT05260671
- Testing
- Penpulimab combined with cetuximab
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Eye & ENT Hospital of Fudan University
GEP-NET, Neuroendocrine Tumors
Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms
Prospective clinical trial investigating combined, dual 18F-FDG PET/CT and 64Cu-DOTATATE PET/CT imaging of patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN)
- Conditions
- GEP-NET, Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Carcinoma Metastatic
- Trial name
- NCT05709171
- Testing
- 18F-FDG, 64Cu-Dotatate
- Where
- Denmark
- Volunteers
- 200 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Pancreatic Ductal Adenocarcinoma, Who Have High CTCs Count in Portal Venous Blood
Application of Intrahepatic Arterial Infusion Chemotherapy for Patients With High Risk of Liver Metastases After Pancreatic Cancer Surgery
Clinical results on intra-arterial adjuvant chemotherapy for prevention of liver metastasis following curative resection of pancreatic cancer
- Conditions
- Pancreatic Ductal Adenocarcinoma, Who Have High CTCs Count in Portal Venous Blood, Liver Metastases
- Trial name
- NCT03687853
- Testing
- Intrahepatic Arterial Infusion
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University Third Hospital
Pancreatic Carcinoma Non-resectable, Metastatic Pancreatic Cancer
Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer
People with pancreatic cancer usually have a large amount of the cancer in the area of the pancreas and around it when they are diagnosed with it.
- Trial name
- NCT00761345
- Testing
- gemcitabine, Erlotinib, low dose fractionated radiotherapy
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Fox Chase Cancer Center
BRCA-Associated Breast Carcinoma
Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation
This study will investigate, in patients with germline BRCA-1/2 mutations and breast cancer, arising during and / or after treatment with platinum-based chemotherapy and / or with PARP-inhibitors for ovarian cancer, the presence…
- Trial name
- Gen-eva (NCT05763472)
- Testing
- Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recurrent Osteosarcoma, Refractory Osteosarcoma
Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma
This phase I/II trial studies the side effects and best dose of hydroxychloroquine and how well it works when given together with gemcitabine and docetaxel in treating participants with osteosarcoma that has come back or does not…
- Trial name
- NCT03598595
- Testing
- Docetaxel, Gemcitabine, Hydroxychloroquine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced or Metastatic Solid Tumors
DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Study DCBY02-101 is a multicenter, open-label, Phase 1 study to assess the effects of anti-CD93 mAb (DCBY02) as a monotherapy in patients with advanced or metastatic solid tumors.
- Trial name
- NCT05496595
- Testing
- DCBY02
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- DynamiCure Biotechnology
Gastrointestinal Stromal Tumor
Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Perioperative imatinib mesylate may shrink the tumor and may reduce the chance of relapse after surgery.
- Trial name
- NCT01267695
- Testing
- imatinib mesylate, conventional surgery
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University
Myelodysplastic Syndrome, Acute Myeloid Leukemia
GVAX vs. Placebo for MDS/AML After Allo HSCT
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational intervention to learn whether the intervention, in this case, the GVAX vaccine, works in preventing MDS…
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT01773395
- Testing
- GVAX, Allogeneic Hematopoietic Stem Cell Transplant, Busulfan
- Where
- 4 sites in United States
- Volunteers
- 123 people
- Sponsor
- Dana-Farber Cancer Institute
BCLC Stage a Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma
BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy
This early phase I trial evaluates the use of hypoxia (lack of oxygen) as a measure in determining the outcome of Y90 selective internal radiation therapy in patients with liver cancer that has spread to a limited number of sites…
- Conditions
- BCLC Stage a Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT05250895
- Testing
- 18F-Fluoromisonidazole, Biopsy, Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Emory University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.